Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles

This article was originally published in The Pink Sheet Daily

Executive Summary

The draft proposal is expected to be a stand-alone clause, not technically part of next year's reauthorization of the Prescription Drug User Fee Act.

You may also be interested in...



User Fees Would Fund Safety Oversight Throughout Product Life Cycles

PDUFA proposal expands scope of funding after FDA concludes that safety problems can occur well after a drug’s launch.

User Fees Would Fund Safety Oversight Throughout Product Life Cycles

PDUFA proposal expands scope of funding after FDA concludes that safety problems can occur well after a drug’s launch.

Pharma DTC Spend Increasing At Twice The Rate Of Physician Promotions, GAO Finds

A Government Accountability Office report, released Dec. 14, calls for improvements in FDA’s oversight of direct-to-consumer advertising.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel